There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
Recruiting
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Multiple Myeloma
Register for Updates
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202
Recruiting
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Associates, Nashville, Tennessee +1 locations
Conditions: Bladder Cancer
Register for Updates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484
Recruiting
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Colitis, Ulcerative
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: TriStar Bone Marrow Transplant, LLC, Nashville, Tennessee
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates
Clareon PanOptix Pro vs. Clareon PanOptix - Study A
NCT06400745
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/18/2024
Locations: Vision for Life, Nashville, Tennessee
Conditions: Aphakia, Presbyopia
Register for Updates
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
NCT06338553
Recruiting
The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under three different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The first meal test is pre-teplizumab, followed by two post-treatment tests, o... Read More
Gender:
All
Ages:
Between 12 years and 50 years
Trial Updated:
06/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Type 1 Diabetes
Register for Updates
Clareon PanOptix Pro vs. Clareon PanOptix - Study B
NCT06401551
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/18/2024
Locations: Vision for Life, Nashville, Tennessee
Conditions: Aphakia, Presbyopia
Register for Updates
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Research Site, Nashville, Tennessee
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471
Recruiting
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Crohn's Disease
Register for Updates
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
NCT05943106
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2024
Locations: Research Site, Nashville, Tennessee
Conditions: Non-Muscle- Invasive Bladder Cancer
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Associates, Nashville, Tennessee
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775
Recruiting
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee +1 locations
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates